Serofin
Serofin, licence 80006429: inactive licence in Health Canada data. The French and European references below do not constitute authorisation for sale in France or an assessment of safety or efficacy.
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
Natural health product licensed in Canada
- Other names
- Mood Take Care
- Licence holder
- New Chapter Inc
- NPN or DIN-HM
- 80006429
- Status
- Inactive licence
- Licence date
- 4 July 2008
- Revision date
- Not provided
- Form
- Gélule
- Route of administration
- Orale
- Application type
- Non traditionnelle
If this product were sold in France
No point flagged by the rules we apply.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
Medicinal composition not provided.
Non-medicinal ingredients
Gélatine, Lécithine, Carob, Glycérine végétale, Eau purifiée, Cire d'abeille jaune, huile d'olive
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | Not specified | 1.0 Gélule | minimum: 1.0 Tous les jours ; maximum: 2.0 Tous les jours |
Uses authorised in Canada
Helps promote healthy mood balance.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
- Précautions et mises en garde
As with any dietary or herbal supplement, you should advise your health care practitioner of the use of this product. If you are taking a prescription medicine, check with a health care practitioner before using. Although phototoxicity in humans is rare, fair-skinned individuals should avoid excessive exposure to sunlight and/or ultra violet light or ultra violet therapy when using St. John's wort. Consult a health care provider if you experience sleep disturbances or taking conventional medication such as immunosuppressants, serotonergic antidepressants, migraine therapies, SSRIs and/or anti-epilepsy drugs. If symptoms persist consult a health care provider.
- Contre-indications
May potentiate pharmaceutical MAO-inhibitors. Use of Hypericum perforatum with pharmaceutical antiretrovirals such as protease inhibitors, non-nuclease reverse transcriptase inhibitors, and other drugs that are similarly metabolized (such as birth control pills, digoxin, cyclosporine, blood thinners, chemotherapy drugs, asthma medications or drugs relating to the treatment of HIV) is not recommended and should be done only under direct supervision of a health care practitioner. Do not use if you are pregnant or breastfeeding.
- Effets indésirables connus
Other potential side effects may include gastrointestinal symptoms, dizziness, tiredness, and mild allergic reactions (skin rash).
Source
Official Health Canada record, licence 80006429
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.